Weight-loss and diabetes drugs prompt about one suspected adverse reaction per day

Infarmed received 266 notifications of suspected adverse reactions to weight-loss and diabetes drugs (GLP-1 receptor agonists) between January 1 and September 21, 2026, averaging about one per day. Since 2024, a total of 695 notifications have been recorded across four active substances—tirzepatide (Mounjaro), semaglutide (Ozempic, Rybelsus), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)—alongside a substantial rise in sales volume, such as tirzepatide rising from 10,689 packs in 2024 to 434,768 in 2025 and 395,369 by June 2026. The most frequently reported adverse effects include nausea (98 cases), vomiting (68), diarrhoea (61), and hair loss (19), with Infarmed noting that the notification rate has remained stable relative to the increased usage.